MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug
Portfolio Pulse from
Mesoblast's stock has surged 80% in the past month after the FDA approved its drug Ryoncil for treating SR-aGVHD in children aged two months and older.
January 03, 2025 | 5:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mesoblast's stock has surged 80% following the FDA's approval of Ryoncil, the only approved therapy for SR-aGVHD in children aged two months and older.
The FDA approval of Ryoncil is a significant milestone for Mesoblast, as it is the only approved therapy for SR-aGVHD in young children. This approval likely boosts investor confidence and demand for MESO stock, leading to an 80% surge.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100